Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 219

The DOI matches its Crossref record.

Population pharmacokinetics and therapeutic response of CGP 56697 (artemether+benflumetol) in malaria patients

Open access
Ezzet, Farkad, Mull, Robert, Karbwang, Juntra·1998·British Journal of Clinical Pharmacology

Abstract

Aims To investigate the pharmacokinetic and pharmacodynamic properties of artemether and benflumetol in a fixed combination tablet (CGP 56697) and to offer an explanation for the lower than expected cure rate in a Thai clinical trial. Methods Two hundred and sixty patients were enrolled into a randomized, double‐blind, parallel group, dose‐finding trial. CGP 56697 was given orally, either as: A, 4×4 tablets over 48 h; B, 4×2 tablets over 48 h or C, 3×4 tablets over 24 h. Each tablet contained artemether 20 mg amd benflumetol 120 mg. The pharmacokinetics were determined using a population‐based approach combining full profiles (42 patients) and sparse data (218 patients). Parasite clearance time and 28 day cure rate were correlated with the derived pharmacokinetic parameters. Results The median absorption half‐life of benflumetol was 5.3 h, with a t max of 10 h and terminal elimination half‐life of 4.5 days. For artemether (and its metabolite, dihydroartemisinin), the corresponding values were 1.9 (1.9) h, 1.8 (1.2) h, and 0.84 (0.43) h. The variability in bioavailability of artemether and dihydroartemisinin was large both between doses and between patients, but was less pronounced for benflumetol. Compared with the first dose, benflumetol bioavailability was estimated to increase three‐fold by the third and fourth doses. Higher artemether or dihydroartemisinin AUC was found to decrease parasite clearance time. Higher benflumetol AUC was found to significantly increase the chance of cure. Conclusions Using a population‐based approach it was confirmed that the pharmacokinetic and pharmacodynamic properties of benflumetol and artemether differ markedly. Benflumetol AUC is associated with cure and the effect of benflumetol when coadministered with artemether is to prevent recrudescence. The mode of action of benflumetol is consistent with its longer elimination half‐life. A short course of low‐dose artemether, which is rapidly absorbed and has a short elimination half‐life, produced effective parasite clearance. The complementary pharmacokinetic and pharmacodynamic properties of benflumetol and artemether was the main rationale for developing a fixed‐dose combination. While the 4×4 dose regimen is very effective in most endemic areas, the poorer absorption (2.5 fold lower than in China) and the more resistant parasites in Thailand require higher doses of this drug.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2125.1998.00830.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 219

Metadata

Authors
Ezzet, F., Mull, R., & Karbwang, J.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
1998-12
Volume
46
Issue
6
Pages
553-561
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1921967810
Cited by
219
References
0
FWCI
8.92
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Population pharmacokinetics and therapeutic response of CGP 56697 (artemether+benflumetol) in malaria patients. https://app.cochat.ai/papers/10.1046/j.1365-2125.1998.00830.x
The paper
Ezzet, F., Mull, R., & Karbwang, J. (1998). Population pharmacokinetics and therapeutic response of CGP 56697 (artemether+benflumetol) in malaria patients. British Journal of Clinical Pharmacology. https://doi.org/10.1046/j.1365-2125.1998.00830.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.